Neurodevelopmental Stimulation of a Child with a Noonan Syndrome with a Non-Frequent Mutation in RAF1 Gene — Case Report
DOI:
https://doi.org/10.15225/PNN.2019.8.2.5Keywords
Noonan syndrome, RAF1 gene mutation, pediatric clinical diagnosis, interdisciplinary rehabilitation, psychomotor development, interventional speech therapyAbstract
Introduction. Noonan syndrome (NS) is a genetically determined disease, inherited from autosomal dominant. About 50% of patients have a mutation in the PTPN11 gene, and mutations in the other genes are much less frequent, up to 10–15% for SOS1, RAF1, and RIT1, as well as up to 1–2% for others.
Aim. To present the clinical picture of a child with NS with a non-frequent mutation in the RAF1 gene and to describe a proposal of good practice based on the multi-specialty child care procedures used from birth to 3 years of age.
Case Report. The paper presents a boy with NS and his psychomotor and linguistic development during the 36 months of his life. The infant was born by cesarean section in average general condition and with features of macrosomia. Castillo-Morales rehabilitation techniques were used to improve the coordination of suction, swallowing and breathing. Bobath Neurodevelopmental Treatment was also used on the hospital ward. The NS child’s development was assessed using the Munich Functional Developmental Diagnostics (MFDD). At the age of 36 months, the boy presents psychomotor development appropriate for the age of a healthy child. He remains under multidisciplinary team care and is intensively rehabilitated accordingly to both movement and linguistic functions.
Discussion. Management of NS should be comprehensive and multidisciplinary, and continuous monitoring of patients is crucial. Although a number of patients experience learning difficulties and a mild form of mental impairment, the diagnosis of NS does not predispose to mental disorders.
Conclusions. NS is a multi-symptomatic disease that manifests itself in the expression of clinical symptoms requiring the interdisciplinary cooperation of many specialists. The fact is that the identified mutation in the RAF1 gene in patients with NS does not mean they are predestined to develop psychomotor disorders. (JNNN 2019;8(2):78–85)
References
Lepri F.R., Scavelli R., Digilio M.C. et al. Diagnosis of Noonan syndrome and related disorders using target next generation sequencing. BMC Med Genet. 2014;15:14.
Bhambhani V., Muenke M. Noonan syndrome. Am Fam Physician. 2014;89(1):37–43.
Bezniakow N., Gos M., Obersztyn E. The RASopathies as an example of RAS/MAPK pathway disturbances — clinical presentation and molecular pathogenesis of selected syndromes. Dev Period Med. 2014;18(3):285–296.
Cizmarova M., Kostalova L., Pribilincova Z. et al. Rasopathies — dysmorphic syndromes with short stature and risk of malignancy. Endocr Regul. 2013;47(4):217–222.
Tidyman W.E., Rauen K.A. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med. 2008;10:e37.
Tartaglia M., Pennacchio L.A., Zhao C. et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007;39(1):75–79.
Gos M., Leszkiewicz M., Abramowicz A. RAS/MAPK signal transduction pathway and its role in the pathogenesis of Noonan syndrome. Postepy Biochem. 2012;58(3):255–264.
Malaquias A.C., Brasil A.S., Pereira A.C. et al. Growth standards of patients with Noonan and Noonan-like syndromes with mutations in the RAS/MAPK pathway. Am J Med Genet A. 2012;158A(11):2700–2706.
Yaoita M., Niihori T., Mizuno S. et al. Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations. Hum Genet. 2016;135(2):209–222.
Nemcikova M., Vejvalkova S., Fencl F., Sukova M., Krepelova A. A novel heterozygous RIT1 mutation in a patient with Noonan syndrome, leukopenia, and transient myeloproliferation-a review of the literature. Eur J Pediatr. 2016;175(4):587–592.
Thompson D., Patrick-Esteve J., Surcouf J.W. et al. RAF1 variants causing biventricular hypertrophic cardiomyopathy in two preterm infants: further phenotypic delineation and review of literature. Clin Dysmorphol. 2017;26(4):195–199.
Markiewicz K., Pachalska M. Diagnosis of severe developmental disorders in children under three years of age. Med Sci Monit. 2007;13(2):CR89–99.
Tafazoli A., Eshraghi P., Koleti Z.K., Abbaszadegan M. Noonan syndrome — a new survey. Arch Med Sci. 2017;13(1):215–222.
Roberts A.E., Allanson J.E., Tartaglia M., Gelb B.D. Noonan syndrome. Lancet. 2013;381(9863):333–342.
Sullivan P.B. Gastrointestinal disorders in children with neurodevelopmental disabilities. Dev Disabil Res Rev. 2008;14(2):128–136.
Romano A.A., Allanson J.E., Dahlgren J. et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126(4):746–759.
van der Burgt I. Noonan syndrome. Orphanet J Rare Dis. 2007;2:4.
Şıklar Z., Genens M., Poyrazoğlu Ş. et al. The Growth Characteristics of Patients with Noonan Syndrome: Results of Three Years of Growth Hormone Treatment: A Nationwide Multicenter Study. J Clin Res Pediatr Endocrinol. 2016;8(3):305–312.
Roelofs R.L., Janssen N., Wingbermühle E., Kessels R.P., Egger J.I. Intellectual development in Noonan syndrome: a longitudinal study. Brain Behav. 2016;6(7):e00479.
Pierpont E.I., Ellis Weismer S., Roberts A.E. et al. The language phenotype of children and adolescents with Noonan syndrome. J Speech Lang Hear Res. 2010;53(4):917–932.
Selås M., Helland W.A. Pragmatic language impairment in children with Noonan syndrome. Clin Linguist Phon. 2016:30(11):899–910.
Roelofs R.L., Wingbermühle E., Freriks K., Verhaak C.M., Kessels R.P., Egger J.I. Alexithymia, emotion perception, and social assertiveness in adult women with Noonan and Turner syndromes. Am J Med Genet A. 2015;167A(4):768–776.
Wingbermühle E., Roelofs R.L., van der Burgt I. et al. Cognitive functioning of adults with Noonan syndrome: a case-control study. Genes Brain Behav. 2012;11(7):785–793.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 174
Number of citations: 0